Alnylam Pharmaceuticals: Promising Advancements in Alzheimer's Treatment With RNA Interference Therapeutics

TipRanksNov 28 09:55 ET

J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Announces Target Price $272

Moomoo NewsNov 28 07:32 ET · Ratings

Alnylam Pharmaceuticals Insider Sold Shares Worth $1,309,853, According to a Recent SEC Filing

MT NewswiresNov 27 17:29 ET

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

Alnylam Pharmaceuticals, Inc.Nov 27 00:00 ET

FDA Begins Review of Alnylam's SNDA for Expanded Amvuttra Use

Zacks Nov 26 08:35 ET

Scotiabank Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $310

Moomoo NewsNov 26 08:32 ET · Ratings